Emerging in the field of excess body fat therapy, retatrutide presents a different method. Beyond many current medications, retatrutide operates as a dual agonist, at once targeting both GLP-like peptide-1 (GLP-1) and glucose-responsive insulinotropic polypeptide (GIP) receptors. The simultaneous stimulation promotes various helpful effects, includ